Amoéba’s ambition is to become the world leader in the treatment of waterborne bacterial risk, wound care and plant protection. We develop and produce a biological biocide, BIOMEBA, an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn.
In the future, the Company is looking at developing new applications such as chronic wound care, estimated at €751 million in the USA, and the biocontrol market for plant protection estimated globally at €1.6Bn. Sales of the BIOMEBA product for use in industrial cooling towers is subject to the Company being granted local regulatory market authorizations. Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the USA, Amoéba is quoted on the compartment C of Euronext Paris.